Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
Daniel Podzamczer(Bellvitge University Hospital), Antonio Rivero(University of Southern California), Adrián Curran(Lexington City Schools), A. López-Lirola, Juan Macı́as(Hospital Universitario de Valme), Luís Morano(Universidad San Pablo CEU), Antonio Navarro-Alcaraz(IrsiCaixa), María Jesús Vivancos(Hospital Universitario Ramón y Cajal), Hernando Knobel(Hospital General de Granollers), Chiara Fanciulli, Eulalia Valencia, Jesús Troya(Hospital Universitario Infanta Leonor), Arkaitz Imaz(Bellvitge University Hospital), Enrique Bernal(Honeywell (United States)), Joaquín Portilla(Hospital General Universitario de Alicante Doctor Balmis), María Casadellà(IrsiCaixa), María Lagarde(Instituto de Salud Carlos III), Ángela Gutiérrez(Hospital Universitario de La Princesa), Marta Montero, Raül Rigo‐Bonnin(Bellvitge University Hospital), Carmen Hidalgo-Tenorio, Mar Masiá(Universidad de Alcalá), Cristina Hernández(Hospital Universitario Príncipe de Asturias), Paula Prieto(Hospital de Sant Pau), Fernando Ardila(Institut d'Investigació Biomédica de Bellvitge), Mariona Parera(IrsiCaixa), Patricia Echeverría(Universitat Autònoma de Barcelona), Vicente Estrada(Instituto de Salud Carlos III)
Cited by 10
Related Papers
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
|Clinical Microbiology and Infection|2020|423